polypyrimidine tract binding protein 2Genealiases: PTBLP · brPTB · nPTB
Q-omics provides the consensus-scored PTBP2 profile across patient tissues and cancer cell-line models. PTBP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PTBP2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, PTBP2 RNA expression shows 20,981 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KICH, and UVM as cancer lineages where PTBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTBP2 survival associations across molecular data types. PTBP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTBP2 RNA expression–survival associations across cancer types. High PTBP2 expression shows unfavorable associations in KICH, ACC, LIHC and UCEC, but favorable associations in UCS and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PTBP2 RNA expression.
This table summarizes PTBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTBP2 shows lower tumor expression in KICH, BLCA, THCA and BRCA and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher PTBP2 RNA expression in normal versus tumor tissue (log2 FC = −1.386, t-test p < 0.001).
This table shows molecular features associated with PTBP2 in patient tissues and cancer cell lines. In patient samples, PTBP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
